Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2021
Jury finds Nevro infringed two Boston Scientific patents
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
2021
Nevro withdraws full-year guidance and provides third-quarter outlook
Nevro withdrew its full-year 2021 guidance and provided third-quarter guidance, expecting worldwide revenue of approximately $90 million to $93 million.
2021
Nevro updates 2021 revenue and adjusted EBITDA guidance
Nevro updated its full-year 2021 worldwide revenue guidance to approximately $440 million to $450 million, from $430 million to $450 million, and its adjusted EBITDA guidance to $5 million to $15 million, from $0 million to $15 million.
2021
Nevro introduces HFX brand identity
Nevro highlighted the introduction of HFX, described as a comprehensive new brand identity combining its technologies, therapies and patient support.
2021
Nevro launches Omnia upgrade powered by HFX Connect in the U.S.
Nevro announced the full U.S. market launch of its Omnia upgrade, now powered by HFX Connect, which enables remote therapy optimization.
2021
Nevro introduces the HFX brand identity
Nevro announced the introduction of its HFX brand and an updated website, presenting HFX as a unified platform for its products, services, and patient support.
2021
Nevro appoints Jon Shear as vice president of corporate development
Nevro announced Jon Shear's appointment to the newly created position of Vice President, Corporate Development, effective immediately.
2020
Nevro and Boston Scientific agree to dismiss California patent case
Nevro and Boston Scientific agreed to dismiss the remaining claims in Nevro's California patent case concerning high-frequency spinal cord stimulation therapy. The dismissal remained subject to court approval; the parties said other patent cases would continue.
2020
Nevro announces Roderick MacLeod as CFO
Nevro announced Roderick ("Rod") MacLeod's appointment as Chief Financial Officer, effective June 15, 2020; he will succeed Andrew Galligan, who is retiring and will remain with the company during a transition period.
2020
Nevro files patent lawsuit against Nalu Medical
Nevro Corp. filed a patent-infringement lawsuit against Nalu Medical in the U.S. District Court for the District of Delaware, alleging that Nalu infringed Nevro patents covering the Senza system and HF10 therapy.
2020
Nevro provides additional 2020 financial guidance
Nevro reiterated its 2020 worldwide revenue range and provided additional guidance for gross margin, operating expenses and adjusted EBITDA.
2020
Nevro reports fourth-quarter and full-year 2019 results
Nevro announced financial results for the fourth quarter and full year ended December 31, 2019, reporting worldwide revenue of $114.4 million for the quarter and $390.3 million for the year.
2019
Nevro appoints Karen N. Prange to its board
Nevro announced that its Board of Directors appointed Karen N. Prange as a board member, effective that day.